Stock Events

Stock Events

Clinuvel Pharmaceuticals 

€4.82
100
-€0.33-6.41% 08:52 Today

Statistics

Day High
4.82
Day Low
4.82
52W High
7.15
52W Low
4.6
Volume
-
Avg. Volume
-
Mkt Cap
243.06M
P/E Ratio
-
Dividend Yield
0.6%
Dividend
0.03

Upcoming

Dividends

0.6%Dividend Yield
Sep 26
€0.03
Sep 25
€0.03
Sep 24
€0.03
Oct 23
€0.03
Oct 22
€0.03
10Y Growth
N/A
5Y Growth
12.47%
3Y Growth
1.2%
1Y Growth
-7.92%

Earnings

26AugExpected
Q4 2025
Q2 2026
0.12
0.18
0.24
0.3
Expected EPS
0.29706374655936
Actual EPS
0.27884117888000004

Financials

-9.97%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
4.24BRevenue
-422.94MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UR9A.STU. It's not an investment recommendation.
Coca-Cola
9
CCC3.F
Microsoft
8
MSF.F
Microsoft
7
MSFT
Alphabet
7
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Icon
ICLR
Mkt Cap12.72B
ICON plc provides clinical research services to the pharmaceutical, biotechnology, and medical device industries, competing in the development and commercialization of dermatological treatments similar to Clinuvel's focus.
Pfizer
PFE
Mkt Cap162.16B
Pfizer Inc. is involved in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products, including treatments in areas that overlap with Clinuvel's therapeutic focus.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, competing in areas such as skin conditions and rare diseases.
Novartis
NVS
Mkt Cap304.1B
Novartis AG researches, develops, manufactures, and markets healthcare products in areas that compete with Clinuvel, including dermatology and rare diseases.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, including skin health products that compete with Clinuvel's portfolio.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson researches and develops, manufactures, and sells a broad range of products in the healthcare field, including competitive offerings in dermatology and rare diseases.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products directly competing in the dermatology and rare disease market segments targeted by Clinuvel.
AMGEN
AMGN
Mkt Cap236.38B
Amgen Inc. focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise, competing in the development of treatments for conditions that Clinuvel also targets.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, including skin diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.88B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including rare genetic diseases that overlap with Clinuvel's focus areas.

About

Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.
Show more...
CEO
Philippe Jacques Wolgen
Employees
100
Country
United States
ISIN
US1887691038
WKN
000A0RM8Z

Listings

F
DE
UR9.F
XNAS
US
CUVL
MU
DE
UR9A.MU
STU
DE
UR9A.STU

0 Comments

Share your thoughts

FAQ

What is Clinuvel Pharmaceuticals stock price today?▼
The current price of UR9A.STU is €4.82 EUR — it has decreased by -6.41% in the past 24 hours. Watch Clinuvel Pharmaceuticals stock price performance more closely on the chart.
What is Clinuvel Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Clinuvel Pharmaceuticals stocks are traded under the ticker UR9A.STU.
Is Clinuvel Pharmaceuticals stock price growing?▼
UR9A.STU stock has fallen by -2.43% compared to the previous week, the month change is a -7.31% fall, over the last year Clinuvel Pharmaceuticals has showed a -18.99% decrease.
What is Clinuvel Pharmaceuticals market cap?▼
Today Clinuvel Pharmaceuticals has the market capitalization of 243.06M
When is the next Clinuvel Pharmaceuticals earnings date?▼
Clinuvel Pharmaceuticals is going to release the next earnings report on February 23, 2027.
What were Clinuvel Pharmaceuticals earnings last quarter?▼
UR9A.STU earnings for the last quarter are 0.28 EUR per share, whereas the estimation was 0.3 EUR resulting in a -6.13% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Clinuvel Pharmaceuticals revenue for the last year?▼
Clinuvel Pharmaceuticals revenue for the last year amounts to 4.24B EUR.
What is Clinuvel Pharmaceuticals net income for the last year?▼
UR9A.STU net income for the last year is -422.94M EUR.
Does Clinuvel Pharmaceuticals pay dividends?▼
Yes, UR9A.STU dividends are paid annual. The last dividend per share was 0.03 EUR. As of today, Dividend Yield (FWD)% is 0.6%.
How many employees does Clinuvel Pharmaceuticals have?▼
As of September 07, 2026, the company has 100 employees.
In which sector is Clinuvel Pharmaceuticals located?▼
Clinuvel Pharmaceuticals operates in the Health & Wellness sector.
When did Clinuvel Pharmaceuticals complete a stock split?▼
The last stock split for Clinuvel Pharmaceuticals was on November 12, 2010 with a ratio of 1:10.
Where is Clinuvel Pharmaceuticals headquartered?▼
Clinuvel Pharmaceuticals is headquartered in Melbourne, United States.